Business
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026
– Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets – – Pivotal Phase 3 trials in wet AMD on
About this update from Eyepoint, Inc.
[{"type":"text","content":"– Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets – – Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-2026 – – Phase 3 DME program first patient dosing expected in Q1 2026 – – Presenting at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 7:30 a.m. PT – WATERTOWN, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today reported a corporate update and anticipated 2026 pivotal milestones for its lead product candidate, DURAVYU™ (vorolanib intravitreal insert). “Following an incredibly successful year of execution in 2025, EyePoint is positioned to deliver on key priorities across both of our late-stage programs, wet AMD and DME, in 2026,” said Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint. “As we prepare for a milestone-rich year, we continue to be guided by scientific rigor, a de-risked clinical approach, and a patient-centric focus that define our principles. With topline data from our Phase 3 wet AMD program anticipated beginning in mid-2026, we are actively preparing for an expeditious NDA filing and FDA review to ensure we deliver DURAVYU to patients as soon as possible. Additionally, we remain on track to dose the first patient in our Phase 3 DME program in the first quarter of 2026, further solidifying DURAVYU’s position as the only sustained release TKI in development for this multi-billion-dollar indication for which there is a significant need for new therapeutic options.” Dr. Duker continued, “DURAVYU is uniquely poised to potentially disrupt the largest retinal disease markets, with a unique multi-mechanism of action, and a compelling profile within the retinal disease community. We remain focused on advancing DURAVYU as a best-in-class and first-in-class sustained delivery therapy to improve the lives of patients with serious retinal diseases.” A Leader in Sustained Ocular Drug Delivery: DURAVYU in Wet Age-Related Macular Degeneration (Wet AMD) Completed enrollment of over 900 patients across the Phase 3 LUGANO and LUCIA trials in 7 months, respectively, representing one of the fastest enro...